1. Home
  2. BCDA vs ENSV Comparison

BCDA vs ENSV Comparison

Compare BCDA & ENSV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • ENSV
  • Stock Information
  • Founded
  • BCDA N/A
  • ENSV N/A
  • Country
  • BCDA United States
  • ENSV United States
  • Employees
  • BCDA N/A
  • ENSV N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • ENSV Oilfield Services/Equipment
  • Sector
  • BCDA Health Care
  • ENSV Energy
  • Exchange
  • BCDA Nasdaq
  • ENSV Nasdaq
  • Market Cap
  • BCDA 9.4M
  • ENSV 7.2M
  • IPO Year
  • BCDA N/A
  • ENSV N/A
  • Fundamental
  • Price
  • BCDA $2.95
  • ENSV $0.21
  • Analyst Decision
  • BCDA Strong Buy
  • ENSV
  • Analyst Count
  • BCDA 1
  • ENSV 0
  • Target Price
  • BCDA $60.00
  • ENSV N/A
  • AVG Volume (30 Days)
  • BCDA 86.1K
  • ENSV 239.6K
  • Earning Date
  • BCDA 08-07-2024
  • ENSV 08-12-2024
  • Dividend Yield
  • BCDA N/A
  • ENSV N/A
  • EPS Growth
  • BCDA N/A
  • ENSV N/A
  • EPS
  • BCDA N/A
  • ENSV N/A
  • Revenue
  • BCDA $468,000.00
  • ENSV $22,938,000.00
  • Revenue This Year
  • BCDA N/A
  • ENSV $36.41
  • Revenue Next Year
  • BCDA $436.41
  • ENSV $18.74
  • P/E Ratio
  • BCDA N/A
  • ENSV N/A
  • Revenue Growth
  • BCDA N/A
  • ENSV 4.39
  • 52 Week Low
  • BCDA $2.62
  • ENSV $0.15
  • 52 Week High
  • BCDA $35.40
  • ENSV $0.50
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 37.81
  • ENSV 42.11
  • Support Level
  • BCDA $2.84
  • ENSV $0.21
  • Resistance Level
  • BCDA $3.66
  • ENSV $0.27
  • Average True Range (ATR)
  • BCDA 0.32
  • ENSV 0.02
  • MACD
  • BCDA 0.09
  • ENSV -0.00
  • Stochastic Oscillator
  • BCDA 17.44
  • ENSV 3.08

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About ENSV Enservco Corporation

Enservco Corp operates in the oil and gas industry. It offers well enhancement and fluid management services to the domestic onshore oil and natural gas industry. The services include frac water heating, hot oiling, pressure testing, acidizing, bacteria and scale treatment, freshwater and saltwater hauling, fluid disposal, frac tank rental, well site construction, and other general oil field services. The company's reportable business segments are Production Services and Completion and Other Services, which derives maximum revenue. It operates in geographically diverse regions of the United States.

Share on Social Networks: